

[Aprepitant](#)

Essential medicine status

Section:

[17. Gastrointestinal medicines](#) [17.2. Antiemetic medicines](#)

ATC codes: [A04AD12](#)

EMLc

Indication

Nausea or vomiting ICD11 code: [MG10](#)

INN

Aprepitant

Medicine type

Chemical agent

List type

Complementary

Formulations

Oral > Liquid: 125 mg powder for oral suspension (in sachet)

Oral > Solid > capsule: 80 mg (EML) ; 125 mg (EML) ; 165 mg (EML)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Aprepitant](#)

DrugBank

[Aprepitant](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the removal from the EMLc of aprepitant capsules (80 mg, 125 mg and 165 mg). These formulations cannot deliver the recommended dose of aprepitant for children aged below 12 years.